IL133104A0 - New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists - Google Patents

New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists

Info

Publication number
IL133104A0
IL133104A0 IL13310498A IL13310498A IL133104A0 IL 133104 A0 IL133104 A0 IL 133104A0 IL 13310498 A IL13310498 A IL 13310498A IL 13310498 A IL13310498 A IL 13310498A IL 133104 A0 IL133104 A0 IL 133104A0
Authority
IL
Israel
Prior art keywords
beta
amino
new
production
acid derivatives
Prior art date
Application number
IL13310498A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL133104A0 publication Critical patent/IL133104A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • C07D237/16Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13310498A 1997-06-19 1998-06-05 New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists IL133104A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19726146A DE19726146A1 (de) 1997-06-19 1997-06-19 Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
PCT/EP1998/003366 WO1998058916A1 (de) 1997-06-19 1998-06-05 NEUE β-AMINO UND β-AZIDOCARBONSÄUREDERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS ENDOTHELINREZEPTORANTAGONISTEN

Publications (1)

Publication Number Publication Date
IL133104A0 true IL133104A0 (en) 2001-03-19

Family

ID=7833081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13310498A IL133104A0 (en) 1997-06-19 1998-06-05 New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists

Country Status (22)

Country Link
EP (1) EP0994861A1 (ja)
JP (1) JP2002504130A (ja)
KR (1) KR20010013981A (ja)
CN (1) CN1261352A (ja)
AR (1) AR015893A1 (ja)
AU (1) AU8213398A (ja)
BG (1) BG104022A (ja)
BR (1) BR9810182A (ja)
CA (1) CA2294050A1 (ja)
CO (1) CO4950605A1 (ja)
DE (1) DE19726146A1 (ja)
HR (1) HRP980331A2 (ja)
HU (1) HUP0002714A3 (ja)
ID (1) ID24346A (ja)
IL (1) IL133104A0 (ja)
NO (1) NO996268L (ja)
NZ (1) NZ502319A (ja)
PL (1) PL337507A1 (ja)
SK (1) SK176299A3 (ja)
TR (1) TR199903159T2 (ja)
WO (1) WO1998058916A1 (ja)
ZA (1) ZA985277B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19858779A1 (de) * 1998-12-18 2000-06-21 Basf Ag Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
EP1632821B1 (en) 2004-09-01 2012-05-30 Océ-Technologies B.V. Intermediate transfer member with a cleaning member
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8217155B2 (en) 2007-07-31 2012-07-10 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
CN109422664B (zh) * 2017-08-23 2022-02-18 中国科学院福建物质结构研究所 一类干扰素调节剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
NO996268D0 (no) 1999-12-17
DE19726146A1 (de) 1998-12-24
NZ502319A (en) 2002-03-01
CN1261352A (zh) 2000-07-26
JP2002504130A (ja) 2002-02-05
ID24346A (id) 2000-07-13
EP0994861A1 (de) 2000-04-26
TR199903159T2 (xx) 2000-07-21
NO996268L (no) 1999-12-17
BG104022A (en) 2001-04-30
HRP980331A2 (en) 1999-02-28
AU8213398A (en) 1999-01-04
SK176299A3 (en) 2000-06-12
WO1998058916A1 (de) 1998-12-30
AR015893A1 (es) 2001-05-30
CO4950605A1 (es) 2000-09-01
ZA985277B (en) 1999-12-20
HUP0002714A2 (hu) 2001-05-28
BR9810182A (pt) 2000-08-08
CA2294050A1 (en) 1998-12-30
KR20010013981A (ko) 2001-02-26
PL337507A1 (en) 2000-08-28
HUP0002714A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
HK1005801A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
EP0763035A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS
EP1007026A4 (en) INTEGRIN ANTAGONISTS
IL123581A0 (en) Pyrimidine derivatives as 5HT2c- receptor antagonists
AU2077795A (en) N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
AU6267198A (en) Amides as npy5 receptor antagonists
HK1026418A1 (en) Novel pyrimidine derivatives and processes for the preparation thereof
HK1030939A1 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
HUP0003484A3 (en) Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
HRP20000002B1 (en) Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
EP0766684A4 (en) ENDOTHELINE RECEPTOR ANTAGONISTS
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
HUP0001603A3 (en) Cycloalkylalkanecarboxamides and the production and use thereof
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
IL133104A0 (en) New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists
IL130251A0 (en) Heterocyclic carboxylic acid derivatives the production and use thereof as endothelin receptor antagonists
IL134057A0 (en) Certain bezothiazine dioxide endothelin antagonists and processes for their preparation
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
EP0768878A4 (en) ENDOTHELINE RECEPTOR ANTAGONISTS
ZA985209B (en) Endothelin antagonists
PL338456A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
AU6826698A (en) Endothelin receptor antagonists

Legal Events

Date Code Title Description
HP Change in proprietorship